Activation of clotting factors XI and IX in patients with acute myocardial infarction

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 11, 2000, Pages 2489-2493

  Minnema, Monique C ^a,b   Peters, R J G ^a   De Winter, R ^a   Lubbers, Y P T ^b   Barzegar, S ^c   Bauer, K A ^c   Rosenberg, R D ^d,e   Hack, C E ^b   Ten Cate, H ^a,f  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

^c VA BOSTON HEALTHCARE SYSTEM   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^f SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

Cardiovascular disease; Coagulation; Myocardial infarction; Thrombosis

Indexed keywords

ALPHA 1 ANTITRYPSIN; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12A; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9; FIBRINOPEPTIDE A; KALLIKREIN INHIBITOR; THROMBOPLASTIN;

ACUTE HEART INFARCTION; ADULT; AGED; ANGINA PECTORIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING; CLINICAL ARTICLE; CORONARY ARTERY THROMBOSIS; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; MALE; PRIORITY JOURNAL; THROMBIN TIME; UNSTABLE ANGINA PECTORIS;

EID: 0033764837     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.11.2489     Document Type: Article

References (39)

1. The pathogenesis of coronary artery disease and the acute coronary syndromes
2. Antithrombotic agents in coronary artery disease
3. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque
4. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes
5. Tissue-factor antigen and activity in human atherosclerotic plaques
6. The coagulation cascade: Initiation, maintenance, and regulation
7. Hyperprolactinemia and reduction in plasma titers of Hageman factor, prekallikrein, and high molecular weight kininogen in patients with acute myocardial infarction
8. Coagulation, fibrinolytic, and inhibitory proteins in acute myocardial infarction and angina pectoris
9. Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris
10. Activation of human blood coagulation factor XI independent of factor XII
11. Factor XI activation in a revised model of blood coagulation
12. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis
13. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor
14. Thrombin-mediated activation of factor XI results in a TAFI (thrombin-activatable fibrinolysis inhibitor) dependent inhibition of fibrinolysis
15. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI: In vivo evidence for a role of factor XI as an anti-fibrinolytic factor
16. Unstable angina: A classification
17. Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: Major role for C-inhibitor
18. Activation of clotting factor XI, without detectable contact activation in experimental human endotoxemia
19. Factor IX is activated in vivo by the tissue factor mechanism
20. Detection of factor X activation in humans
21. Plaque fissuring: The cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina
22. Inactivation of factor XIa in vivo: Studies in chimpanzees and in humans
23. 1-antitrypsin in plasma, a contact phase-activated coagulation factor-inhibitor complex, in patients with coronary artery disease
24. Prothromhin activation fragment 1+2 and thrombin antithrombin III complexes in patients with angina pectoris: Relation to the presence and severity of coronary atherosclerosis
25. Factor XIa induced activation of the intrinsic cascade in vivo
26. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor
27. Activation of coagulation after administration of tumor necrosis factor to normal subjects
28. Increased activation of the hemostatic system in men at high risk of fatal coronary heart disease
29. Fibrinopeptide A: A marker of acute coronary thrombosis
30. Fibrinopeptide A and platelet factor levels in unstable angina pectoris
31. Myocardial infarction associated with severe factor-XII deficiency
32. Defective intrinsic fibrinolytic activity in a patient with severe factor XII-deficiency and myocardial infarction
33. Myocardial infarction with normal coronary arteries and factor XII deficiency
34. Depression of factor XII-dependent fibrinolytic activity in survivors of acute myocardial infarction at risk of reinfarction
35. Measurement of activated factor XII in health and disease
36. Coagulation-dependent inhibition of fibrinolysis: Role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma
37. A novel approach to arterial thrombolysis
38. Direct thrombin inhibitors: Appraisal of the antithrombotic/ hemorrhagic balance
39. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: A randomised trial